Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population.

Taylor JM, Kieneker LM, de Borst MH, Visser ST, Kema IP, Bakker SJL, Gansevoort RT.

Kidney Int Rep. 2016 Dec 31;2(3):366-379. doi: 10.1016/j.ekir.2016.12.007. eCollection 2017 May.

2.

Prevalence and Effects of Functional Vitamin K Insufficiency: The PREVEND Study.

Riphagen IJ, Keyzer CA, Drummen NEA, de Borst MH, Beulens JWJ, Gansevoort RT, Geleijnse JM, Muskiet FAJ, Navis G, Visser ST, Vermeer C, Kema IP, Bakker SJL.

Nutrients. 2017 Dec 8;9(12). pii: E1334. doi: 10.3390/nu9121334.

3.

Screening for elevated albuminuria and subsequently hypertension identifies subjects in which treatment may be warranted to prevent renal function decline.

Özyilmaz A, de Jong PE, Bakker SJL, Visser ST, Thio C, Gansevoort RT; PREVEND Study Group.

Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii200-ii208. doi: 10.1093/ndt/gfw414.

PMID:
28031343
4.

The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention.

Özyilmaz A, Boersma C, Visser ST, Postma MJ, de Jong-van den Berg LT, Lambers-Heerspink HJ, de Jong PE, Gansevoort RT.

Eur J Prev Cardiol. 2016 May;23(8):847-55. doi: 10.1177/2047487315604310. Epub 2015 Sep 10.

PMID:
26358992
5.

Statin use and cognitive function: population-based observational study with long-term follow-up.

Joosten H, Visser ST, van Eersel ME, Gansevoort RT, Bilo HJ, Slaets JP, Izaks GJ.

PLoS One. 2015 Feb 6;10(2):e0118045. doi: 10.1371/journal.pone.0118045. eCollection 2015.

6.

Statin use and cognitive function: population-based observational study with long-term follow-up.

Joosten H, Visser ST, van Eersel ME, Gansevoort RT, Bilo HJ, Slaets JP, Izaks GJ.

PLoS One. 2014 Dec 26;9(12):e115755. doi: 10.1371/journal.pone.0115755. eCollection 2014.

7.

24 h urinary free cortisol in large-scale epidemiological studies: short-term and long-term stability and sources of variability.

Rosmalen JG, Kema IP, Wüst S, van der Ley C, Visser ST, Snieder H, Bakker SJ.

Psychoneuroendocrinology. 2014 Sep;47:10-6. doi: 10.1016/j.psyneuen.2014.04.018. Epub 2014 May 4.

8.

Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.

de Vries FM, Denig P, Visser ST, Hak E, Postma MJ.

Value Health. 2014 Mar;17(2):223-30. doi: 10.1016/j.jval.2013.12.010.

9.

Is combined use of SSRIs and NSAIDs associated with an increased risk of starting peptic ulcer treatment?

Pouwels KB, Kalkman GA, Schagen D, Visser ST, Hak E.

Br J Clin Pharmacol. 2014 Jul;78(1):192-3. doi: 10.1111/bcp.12300. No abstract available.

10.

Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis.

Pouwels KB, Visser ST, Bos HJ, Hak E.

Drug Saf. 2013 Nov;36(11):1079-86. doi: 10.1007/s40264-013-0085-z.

PMID:
23832709
11.

The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges.

Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma MJ.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):285-92. doi: 10.1586/erp.13.20.

PMID:
23763527
12.

Effect of pravastatin and fosinopril on recurrent urinary tract infections.

Pouwels KB, Visser ST, Hak E.

J Antimicrob Chemother. 2013 Mar;68(3):708-14. doi: 10.1093/jac/dks419. Epub 2012 Oct 30.

13.

Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.

Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C.

Am J Manag Care. 2011 Sep;17(9):609-16.

14.

Association of cognitive function with albuminuria and eGFR in the general population.

Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, Bilo HJ, Gansevoort RT.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1400-9. doi: 10.2215/CJN.05530610. Epub 2011 May 12.

15.
16.

Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.

Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ; Prevention of Renal and Vascular End Stage Disease Study Group.

Clin Ther. 2010 Jun;32(6):1103-21. doi: 10.1016/j.clinthera.2010.06.013.

PMID:
20637965
17.

Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.

Tu HA, Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LT, Postma MJ.

Clin Ther. 2010 Jan;32(1):133-44. doi: 10.1016/j.clinthera.2010.01.015.

PMID:
20171419
18.

Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.

Boersma C, Voors AA, Visser ST, de Jong-van den Berg LT, Postma MJ.

Am J Cardiovasc Drugs. 2010;10(1):49-54. doi: 10.2165/11319570-000000000-00000.

PMID:
20104934
19.

Antibiotic usage, dosage and course length in children between 0 and 4 years.

de Jong J, van den Berg PB, Visser ST, de Vries TW, de Jong-van den Berg LT.

Acta Paediatr. 2009 Jul;98(7):1142-8. doi: 10.1111/j.1651-2227.2009.01309.x. Epub 2009 Apr 21.

PMID:
19397542
20.

Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006.

Trip AM, Visser ST, Kalverdijk LJ, de Jong-van den Berg LT.

Br J Clin Pharmacol. 2009 Apr;67(4):466-8. doi: 10.1111/j.1365-2125.2009.03373.x.

21.

Replacing hormone therapy--is the decline in prescribing sustained, and are nonhormonal drugs substituted?

Vegter S, Kölling P, Töben M, Visser ST, de Jong-van den Berg LT.

Menopause. 2009 Mar-Apr;16(2):329-35. doi: 10.1097/gme.0b013e31818c046b.

PMID:
19188855
22.

Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events.

Boersma C, Postma MJ, Visser ST, Atthobari J, de Jong PE, de Jong-van den Berg LT, Gansevoort RT; PREVEND Study Group.

Br J Clin Pharmacol. 2008 May;65(5):723-32. doi: 10.1111/j.1365-2125.2008.03097.x. Epub 2008 Jan 30.

23.

The effect of screening for cardio-renal risk factors on drug use in the general population.

Atthobari J, Gansevoort RT, Visser ST, de Jong PE, de Jong-van den Berg LT; PREVEND study group.

Br J Clin Pharmacol. 2007 Dec;64(6):810-8.

24.

The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate.

Atthobari J, Gansevoort RT, Visser ST, de Jong PE, de Jong-van den Berg LT; PREVEND Study Group.

Br J Clin Pharmacol. 2007 Feb;63(2):224-31.

25.

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.

Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jong-van den Berg LT; PREVEND study group.

Nephrol Dial Transplant. 2006 Nov;21(11):3106-14. Epub 2006 May 23.

PMID:
16720593
26.

Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands.

Klok RM, Boersma C, Oosterhuis I, Visser ST, de Jong-van den Berg LT, Postma MJ.

Aliment Pharmacol Ther. 2006 Jun 1;23(11):1595-600.

Supplemental Content

Loading ...
Support Center